Interferon-induced vitiligo in hepatitis C patients: A case series

International Journal of Dermatology

Volumn 49, Issue 7, 2010, Pages 829-833

  Hamadah, Issam ^a   Binamer, Yousef ^a   Sanai, Faisal M ^b   Abdo, Ayman A ^c   Alajlan, Abdulmajeed ^c  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Riyadh Military Hospital ^*  (Saudi Arabia)

^c KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETAMETHASONE DIPROPIONATE; CORTICOSTEROID; PEGINTERFERON ALPHA; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DEPIGMENTATION; DISEASE DURATION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; HASHIMOTO DISEASE; HEPATITIS C; HUMAN; HYPOPIGMENTATION; HYPOTHYROIDISM; MALE; SKIN EXAMINATION; SKIN REDNESS; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; VITILIGO; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RIBAVIRIN; VITILIGO;

EID: 77954159264     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04443.x     Document Type: Article

References (40)

1. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002, 107:133-144.
2. Sacchi S, Kantarjian H, O'Brien S. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995, 13:2401-2407.
3. Seckin D, Durusoy C, Sahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol 2004, 21:577-579.
4. Stadler R, Mayer-da-Silva A, Bratzke B. Interferons in dermatology. J Am Acad Dermatol 1989, 20:650-656.
5. Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokines therapy. J Am Acad Dermatol 1995, 33:393-410.
6. Guillot B, Blazquez L, Bessis D. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology 2004, 208:49-54.
7. Tinio P, Hadi A, Al-Ghaithi K. Segmental vitiligo and hair curling after interferon alpha and ribavirin treatment for hepatitis C. Skinmed 2006, 5:50-51.
8. Quesada JR, Talpaz M, Rios A. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986, 4:234-243.
9. Conlon KC, Urba WJ, Smith JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990, 65:2237-2242.
10. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991, 115:178-183.
11. D'Hondt L, Delannoy A, Docquier C. Hypothyroidism and arthritis during interferon therapy. Clin Rheumatol 1993, 12:415-417.
12. Hrstic I, Huic D, Bilusic M, Vucelic B. Autoimmune disorders during interferon therapy in a patient with chronic hepatitis C infection: how many of them can be observed in a single patient? J Clin Gastroenterol 2006, 40:367-368.
13. Sagir A, Wettstein M, Heintges T, Haussinger D. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Dig Dis Sci 2002, 47:562-563.
14. Cauli C, Serra G, Chessa L. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin. Haematologica 2006, 91(6 Suppl).
15. Moore MM, Elpern DJ, Carter DJ. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol 2004, 140:215-217. 16- A survey
16. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996, 24:38-47.
17. Kontorinis N, Garas G, Young J. Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic. Intern Med J 2004, 34:519.
18. Chamberlain AJ, Poon E. Cutaneous reactions to interferon and ribavirin. Intern Med J 2004, 34:519.
19. Akay BN, Ekmekci P, Sanli H. Cutaneous, pulmonary and hepatic sarcoidosis associated with autoimmune complications during interferon-alpha treatment for hepatitis C virus infection. J Eur Acad Dermatol Venereol 2006, 20:442-445.
20. Yavorkovosky L, Carrum G, Bruce S, McCarthy PL. Cutaneous sarcoidosis in a patient with Philadelphia-positive chronic myelogenous leukemia treated with interferon-alpha. Am J Hematol 1998, 58:80-81.
21. Kikawada M, Ichinose Y, Kunisawa A. Sarcoidosis induced by interferon therapy for chronic myelogenous leukaemia. Respirology 1998, 3:41-44.
22. Papastathopoulos K, Bouzas E, Naoum G. Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection. J Infect 2006, 52:e59-e61.
23. Bernstein D, Reddy KR, Jeffers L, Schiff E. Canities and vitiligo complicating interferon therapy for hepatitis C. Am J Gastroenterol 1995, 90:1176-1177.
24. Tomasiewicz K, Modrzewska R, Semczuk G. Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: a case report. Adv Ther 2006, 23:139-142.
25. Primo J, Merino C, Gomez Belda AB. Vitiligo and alopecia in patients with chronic hepatitis C treated with alpha interferon associated or not with ribavirin. Gastroenterol Hepatol 2000, 23:362-363.
26. Simsek H, Savas C, Akkiz H, Telatar H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology 1996, 193:65-66.
27. Nouri K, Busso M, Machler BC. Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C. Cutis 1997, 60:289-290.
28. Gogas H, Ioannovich J, Dafni U. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-760.
29. Le Gal FA, Paul C, Chemaly P, Dubertret L. More on cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1996, 35:650-651.
30. Scheibenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 1994, 30A:1209-1211.
31. Harris J, Bines S, Das Gupta T. Therapy of disseminated malignant melanoma with recombinant alpha 2b-interferon and piroxicam: clinical results with a report of an unusual response-associated feature (vitiligo) and unusual toxicity (diffuse pulmonary interstitial fibrosis). Med Pediatr Oncol 1994, 22:103-106.
32. Harfast B, Huddlestone JR, Casall P. Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. J Immunol 1981, 127:2146-2150.
33. Lindhal P, Leary R, Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 1972, 69:721-725.
34. Scultz RM, Papamatheakis JD, Chirgos MA. Interferon: an inducer of macrophage activation by polyanions. Science 1977, 197:674-676.
35. Gidlund M, Orn A, Wigzell H. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978, 273:759-761.
36. Revel M, Chebath J. Interferon activated genes. Trends Biol Sci 1986, 11:166-170.
37. Burman P, Tötterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long-term therapy with leukocyte derived interferon. J Clin Endocrinol Metab 1986, 63:1086-1090.
38. Sztein MB, Steeg PS, Johnson HM, Oppenheim JJ. Regulation of human peripheral blood monocyte DR antigen expression in vitro by lymphokines and recombinant interferons. J Clin Invest 1984, 73:556-565.
39. Todd JA, Acha-Orbea H, Bell JI. A molecular basis for MHC class II - associated autoimmunity. Science 1988, 240:1003-1009.
40. Anbar TS, Abdel-Rahman AT, Ahmad HM. Vitiligo occurring at site of interferon-α 2b injection in a patient with chronic viral hepatitis C: a case report. Clin Exp Dermatol 2008, 33:503.